VITAL Trial: Vitamin D for Prevention of Cancer and CV disease

VITAL Trial (Vit D3) Summary

The VITAL trial (Vit D3) was a randomized, two-by-two factorial design, placebo-controlled trial to assess whether supplementation with Vitamin D3 reduces risks of cardiovascular disease and cancer in a healthy, USA, adult population of 25,871 men of age ³ 50 and women age ³ 55. 12,933 people were assigned to take 2000 IU of daily Vitamin D3, and 12,938 people were assigned to take a placebo.

Supplementation with Vitamin D3 did not result in a significant difference in the primary outcomes. Of the group treated with Vitamin D3, there were 396 events of MI, stroke, or death from cardiovascular causes which did not significantly differ from the 409 events in the placebo group (HR 0.97; 95% CI of 0.85 to 1.12; p=0.69). Of the group treated with Vitamin D3, there were 793 diagnoses of invasive cancer which did not significantly differ from the 824 events in the placebo group (HR 0.96; 95% CI of 0.88 to 1.06; p=0.47).

Thus, the authors of the VITAL trial concluded that supplementation with Vitamin D3 did not result in a lower incidence of major cardiovascular events or cancer than placebo.

Key Point:

  1. Vitamin D3 supplementation does not decrease incidence of cardiovascular events or cancer
  2. This same population was studied for a VITAL trial showing that n-3 fatty acid supplementation does not decrease incidence of cardiovascular events or cancer